연구 보고서

개요
가. 정의
○ 세포치료제란 자가(autologous), 동종(allogenic) 또는 이종(xenogenic)으로부터 얻은 조직이나 세포를 조작, 분리배양, 분화시켜 질환으로 손상된 장기나 인체부위에 이식 또는 대체하는 기술
○ 직접적인 세포 주입으로 손상된 세포의 기능이나 조직을 회복하는 기술과 수지상세포(Dentritic cell) 또는 자연살해세포(Natural killer cell) 등을 주입하는 항암치료법으로 분류
목차
1. 기술개요 ············································1
가. 정의 ···························································1
나. 핵심기술 ························································1
2. 서지분석 ············································2
가. 특허분석 ························································2
1) 특허로 살펴본 세포치료제 세계동향 ·······························2
2) 특허로 살펴본 세포치료제 국내동향 ······························4
나. 논문분석 ························································5
1) 논문으로 살펴본 세포치료제 세계동향 ·····························5
2) 논문으로 살펴본 세포치료제 국내동향 ····························7
다. 시장성 분석․관련산업동향 ········································9
3. 기술개발동향 ·······································12
가. 세계동향 ·······················································12
1) 총괄 국외기술발전도 ···········································12
2) 주요 경쟁자 ··················································13
나. 국내동향 ·······················································15
1) 총괄국내기술발전도 ···········································15
2) 관련수행과제 ·················································16
3) 국내주요연구자 ················································16
4. 국내외 기술수준비교 ·································21
가. 기술수준비교 ···················································21
나. SWOT 분석 ···················································22
5. 기대효과 ···········································23
가. 기술적 효과 ····················································23
나. 경제 산업적 효과 ··············································23
6. 참고문헌 ···········································24
별첨 1. 세포치료제 분야 특허분석
별첨 2. 세포치료제 분야 논문분석
-
이전글
- 형질전환동물 및 이종장기
-
다음글
- 줄기세포
지식
동향